Miraculins Inc.
TSX VENTURE : MOM

Miraculins Inc.

May 27, 2005 11:30 ET

Dr. Vincent Lenaerts Joins Miraculins' Board of Directors

WINNIPEG, MANITOBA--(CCNMatthews - May 27, 2005) - Miraculins Inc. (TSX VENTURE:MOM), a biotechnology company engaged in the discovery and development of products for select cancers, is pleased to announce the addition of Dr. Vincent Lenaerts to the Company's Board of Directors. Dr. Lenaerts is well known and respected in the field of pharmaceutical sciences and has over 20 years experience in management and commercialization of life sciences technologies.

"Vincent is highly regarded in the life sciences community and we are excited about the valuable experience he brings to our board," stated Dr. Jim Charlton, President of Miraculins Inc. "He has a track-record of success that will serve the Company as we move towards capitalizing on the commercial potential of the BEST™ platform for diagnostic test development."

Miraculins recently announced positive results of its study to improve the diagnosis of prostate cancer. By using Miraculins diagnostic approach, the Company was able to correctly identify cancer positives while correctly classifying those without cancer with a sensitivity and specificity of greater than 90-90%.

"The Company has a tremendous amount of promise based upon its scientific progress, market potential and management," commented Dr. Vincent Lenaerts. "I am truly excited to be joining Miraculins' team at this significant time in its corporate development."

Dr. Lenaerts was nominated and elected to the Company's Board of Directors at today's Annual General and Special Meeting of the Shareholders of Miraculins. Miraculins has granted 75,000 options with an exercise price of $1.95 to Dr. Lenaerts. The options are set to expire five years from the date of grant. Dr. Lenaerts' appointment to the Company's Board of Directors is subject to regulatory approval.

About Dr. Vincent Lenaerts

Dr. Lenaerts is an entrepreneur with a track record of successful company creation and development. In 1991 he co-founded Europeptides in Paris, France, a company focusing on the discovery and development of peptidic drugs. The Company was sold to AstaMedica, a subsidiary of Degussa, in 1995. He then co-founded Labopharm, a drug delivery company traded on the Toronto Stock Exchange since 1996 (ticker DDS). In 2003 he became President and CEO of Bioxalis Medica, a biopharmaceutical company specialized in targeted blood vessel destruction in tumors.

In recognition of his achievements in technological innovation and successful commercialization, Dr. Lenaerts was honoured with the J.-Armand Bombardier Award for Technological Innovation, awarded by the ACFAS, in 1999. Dr. Lenaerts has a Bachelor of Pharmacy, a Masters of Science in Industrial Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Louvain in Belgium.

About Miraculins Inc.

Miraculins is a biotechnology company focused on research and development using its proprietary BEST™ platform for the screening and identification of target proteins and peptides related to diseases. The Company is developing products for the diagnosis and treatment of select cancers. Its lead product focuses on improving the diagnosis of prostate cancer. The Company continues to evaluate opportunities to expand its focus and initiate studies in additional disease conditions.

Prostate cancer is responsible for greater than 240,000 new diagnoses in North America each year. The current screening standard for prostate cancer, PSA, is ineffective at reliably distinguishing between non-life threatening prostate conditions and critical prostate cancer. In spite of this fact, there are greater than 25 million PSA tests performed annually in the United States alone, resulting in one million prostate biopsy procedures. An estimated 75% of these procedures are unnecessary and could be avoided if a superior alternative to PSA were available.

Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.

Contact Information